Bowel Cancer Screening Kits Cut Mortality Less Than Follow-Up Scans
The fecal immunochemical test is the workhorse of bowel cancer screening in England, Australia, and much of Europe. It arrives in a plain envelope, costs the health system very little, and flags hidden blood that might indicate a tumour. The mortality reduction attributed to screening programmes, however, depends less on the kit itself than on what happens after a positive result. The colonoscopy is where the deaths are actually prevented.
The gap between kit and colonoscopy
Millions of FIT kits are posted each year to people in their fifties, sixties, and seventies. The test is simple: collect a small stool sample, return it by post, wait for a letter. A negative result buys two more years of reassurance. A positive result triggers a referral for colonoscopy, the camera test that can both find cancer and remove the precancerous polyps that would otherwise become one.
The problem is the interval between the two. A positive FIT is not a diagnosis; it is a signal that something in the bowel is bleeding. The colonoscopy is the diagnostic procedure, and it is also the therapeutic one. If the camera never happens, or happens months later, the mortality benefit of the screening programme shrinks. This site has argued before that screening guidelines assume a colonoscopy within reach, and that assumption does not always hold.
Waiting times vary widely by region. In some health systems, a positive FIT leads to a colonoscopy within two weeks. In others, the wait stretches to several months. The difference is not trivial. A polyp removed early is a cancer prevented; a cancer found late is a harder treatment pathway with worse odds.
Take the example of a 62-year-old man who returns his kit in the spring. The letter arrives three weeks later asking him to call the surgery. He does, and the GP makes an urgent referral. The hospital sends an appointment for eight weeks' time. By then, the polyp that bled has grown. Had the colonoscopy happened at four weeks, it might have been removed in the same session. At twelve weeks, it may require surgery. The exact threshold is debated, but the direction is clear: longer waits mean more advanced disease. This is not a rare scenario; it is the everyday arithmetic of endoscopy capacity.
What the trials actually measured
The evidence base for FIT screening is strong but narrow. Randomised trials and large cohort studies show that offering FIT to a healthy population reduces deaths from colorectal cancer, largely because the test identifies people who need a colonoscopy and the colonoscopy removes polyps before they turn malignant. The test itself does not treat anything.
Colonoscopy, by contrast, is both diagnostic and preventive. It can visualise the entire colon, biopsy suspicious lesions, and snare polyps in the same session. The mortality reduction attributed to colonoscopy is therefore larger than that of FIT alone, because the intervention happens at the point of the test rather than after a second appointment.
The pathway matters as much as the test. A programme that mails kits but cannot guarantee timely follow-up will show a smaller mortality benefit than a programme that tracks every positive result to a completed colonoscopy. Adherence to follow-up is the variable that health systems struggle with most, and it is the one that determines whether the screening investment pays off.
Consider the trade-off between sensitivity and specificity. Lowering the FIT threshold catches more cancers but generates more false positives, each requiring a colonoscopy. Raising it reduces unnecessary procedures but may miss early lesions. Programme managers must balance these against endoscopy capacity. When capacity is tight, the threshold may be raised, which shifts the burden back to the kit and away from the camera. The mortality benefit then depends on whether the missed lesions were the aggressive ones.
A patient's two-week wait
The kit arrives in a plain envelope with no return address that identifies the contents. That discretion is deliberate. The instructions are simple: collect the sample, date the tube, post it back. For most people, the result is negative and the episode ends there. For a minority, the letter comes back with a request to contact the GP surgery.
That phone call starts a sequence that is familiar to anyone who has navigated a two-week wait. The GP makes an urgent referral. The hospital sends an appointment letter. The patient reads about bowel preparation, fasting, sedation, and the small but real risk of perforation. The anxiety in that interval is not a side effect of the system; it is a feature of it, and it is poorly measured.
The colonoscopy slot is the scarce resource. Endoscopy units run lists with limited capacity, and a positive FIT competes with symptomatic referrals, surveillance cases, and other urgent work. In some areas, the wait is short. In others, it is long enough that patients drop off the list entirely, either because they move, lose the letter, or decide they feel fine.
One patient I spoke to described the wait as a countdown without a clock. She had returned her kit in January, received the positive result in February, and had her colonoscopy in May. In that time, she lost her job and her insurance. The colonoscopy found a benign polyp, but the anxiety had already done its damage. Her story is not unique; it illustrates how social factors can derail a clinical pathway.
Why follow-up scans matter more
The colonoscopy is where the mortality benefit is realised. A FIT can flag possible cancer, but it cannot remove a polyp or take a biopsy. The camera can do both. That is why the follow-up scan is not an optional add-on to screening; it is the active ingredient.
Delayed follow-up worsens outcomes. A polyp that could have been removed at an early colonoscopy may grow into a cancer that requires surgery, chemotherapy, or both. The delay may be measured in months, but the biological clock runs in years. Health systems that track kit returns but not colonoscopy completion are measuring the wrong endpoint.
Some programmes now send reminders to patients with a positive FIT who have not booked their colonoscopy. Others use nurse-led navigation to help patients arrange the appointment, understand the preparation, and manage transport. The evidence on these interventions is mixed but generally supportive. The common thread is that someone has to own the follow-up.
Data from several European programmes suggest that around one in five patients with a positive FIT do not undergo colonoscopy within a year. The reasons are multifactorial, but the consequence is a missed opportunity for prevention. If that proportion were reduced to one in ten, the mortality benefit would likely improve, though the exact gain is hard to quantify without long-term follow-up.
The cost of a missed follow-up
Not everyone with a positive FIT gets a colonoscopy. Some never book the appointment. The reasons are practical and psychological: fear of the procedure, embarrassment about bowel preparation, difficulty taking time off work, lack of transport, and cost where a co-payment applies. A related piece on this site describes how mental health coverage shrinks faster than depression rates after job loss, and the same logic applies here: coverage on paper is not the same as access in practice.
GP recall systems vary widely. Some practices have a dedicated administrator who flags overdue follow-ups. Others rely on the patient to re-contact the surgery. The variation is not explained by clinical need. It is explained by staffing, software, and whether anyone has been given the time to chase.
Nurse-led navigation improves uptake in several published evaluations. A nurse who calls the patient, explains the preparation, and books the slot removes friction that a letter cannot. The cost of that call is small compared with the cost of treating an advanced cancer that a timely polyp removal would have prevented.
The financial argument extends beyond the individual. A colonoscopy costs the health system a few hundred euros or pounds, depending on the setting. Treating stage III colorectal cancer costs tens of thousands, plus lost productivity and informal care. The return on investment for follow-up navigation is therefore high, even if the evidence base for specific programmes is still developing. The trade-off is not whether to fund navigation, but how to scale it without diverting resources from the camera itself.
What patients and GPs can do now
Return the kit on time. The test only works if the sample reaches the laboratory within the window specified in the instructions, and a kit left in a drawer is a screening opportunity lost.
If the result is positive, ask for the colonoscopy date before leaving the GP surgery. A referral without a booked appointment is not a plan; it is an intention, and intentions get lost.
GPs can flag overdue follow-ups in the practice recall system. A simple search for positive FIT results without a corresponding colonoscopy report will identify patients who have fallen through the gap.
Consider direct-access endoscopy where it is available. Some health systems allow GPs to refer straight to the endoscopy unit without a specialist outpatient appointment, which shortens the pathway by weeks.
Discuss family history at the next check-up. A first-degree relative with colorectal cancer changes the risk calculation and may justify earlier or more frequent screening than the standard programme offers.
This article is informational and does not constitute personalised medical advice. Anyone with symptoms or a positive screening result should consult their own clinician.
